These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9026942)

  • 1. [The use of interferon-alfa (reaferon) in patients with chronic myeloleukemia].
    Machiulaĭtene ER; Lasunskaia EB; Nefedova IuB; Perekalina TA; Salogub GN; Poliakova LE
    Ter Arkh; 1996; 68(10):44-7. PubMed ID: 9026942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Experience with the use of reaferon (alfa 2-interferon) for treating patients with chronic myeloleukemia].
    Abdulkadyrov KM; Moiseev SI; Shcherbakova EG; Balashova VA; Glazanova TV; Rukavitsyn OA; Martynkevich IS; Gritsaev SV; Blinov MN
    Ter Arkh; 1995; 67(6):59-63. PubMed ID: 7667786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The treatment of chronic myeloleukemia with recombinant alfa-2 interferon].
    Strozha I; Petukhov V; Bondare D; Feldmane G; Duks A; Teilane I; Medne I; Mauritsas M; Grinberga L
    Ter Arkh; 1993; 65(10):62-6. PubMed ID: 8296238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recombinant alpha-interferon (reaferon) in the treatment of patients with chronic myeloleukemia].
    Khoroshko ND; Savchenko VG; Kholopova EI; Kotel'nikov VM; Zakharova AV; Semenova EA; Marchenko VI
    Ter Arkh; 1990; 62(7):41-7. PubMed ID: 2251664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A comparative analysis of the effect of alpha 2-interferon (reaferon) therapy on the morphofunctional state of the bone marrow in patients with chronic myeloleukemia].
    Abdulkadyrov KM; Rukavitsyn OA; Moiseev SI; Rugal' VI
    Gematol Transfuziol; 1993 Mar; 38(3):11-3. PubMed ID: 8020725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interferon alfa-2b treatment of adult patients during early chronic phase of Ph1-positive chronic myeloid leukemia (initial report on a cooperative study, protocol CML-MIG-97)].
    Khoroshko ND; Turkina AG; Zakharova AV; Kobzev IuN; Domracheva EV; Tikhonova LIu; Semenova EA; Zhuravlev VS; Sokolova MA; Kuznetsov SV
    Ter Arkh; 1999; 71(7):42-7. PubMed ID: 10481867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Low doses of alpha-interferon preparations in the treatment of patients with chronic myeloleukemia].
    Abdulkadyrov KM; Udal'eva VIu; Rukavitsyn OA; Bessmel'tsev SS
    Ter Arkh; 2000; 72(7):22-7. PubMed ID: 10983316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined therapy interferon and chemotherapy in chronic myelogenous leukemia.
    Guilhot F; Dreyfus B; Desmarest MC; Giraud C; Huret JL; Brizard A; Tanzer J
    Nouv Rev Fr Hematol (1978); 1989; 31(2):171-3. PubMed ID: 2771633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The use of Ukrainian laferon in the combined treatment of patients with chronic myeloid leukemia].
    Tretiak NM; Bondar MV; Koval' AI; Slavchenko IIu; Mnyshenko VM; Vakul'chuk OM; Hordiienko AI
    Lik Sprava; 1999 Jul; (5):131-4. PubMed ID: 10822701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The efficacy of treatment with native lymphoblast alpha-interferon (Wellferon) in patients with chronic myeloleukemia].
    Abdulkadyrov KM; Rukavitsyn OA; Bessmel'tsev SS; Udal'eva VIu; Martynkevich IS
    Lik Sprava; 1998 Jun; (4):108-13. PubMed ID: 9784720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Alpha-2a-interferon (Reaferon) in the treatment of patients with multiple myeloma].
    Bessmel'tsev SS; Abdulkadyrov KM
    Vopr Onkol; 1999; 45(4):393-7. PubMed ID: 10532098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A modern therapeutic strategy in Ph-positive chronic myeloleukemia].
    Khoroshko ND; Turkina AG; Zhuravlev VS; Sokolova MA; Mikhaĭlova IN; Zakharova AV; Domracheva EV; Semenova EA
    Ter Arkh; 1996; 68(7):22-7. PubMed ID: 8928067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
    Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R
    Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Elmaagacli AH; Beelen DW; Schaefer UW
    Bone Marrow Transplant; 1997 Dec; 20(12):1045-55. PubMed ID: 9466277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated circulating levels of tumor necrosis factor predict unresponsiveness to treatment with interferon alfa-2b in chronic myelogenous leukemia.
    Herrmann F; Helfrich SG; Lindemann A; Schleiermacher E; Huber C; Mertelsmann R
    J Clin Oncol; 1992 Apr; 10(4):631-4. PubMed ID: 1548526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha interferon: perspectives in the biotherapy of chronic myelogenous leukemia.
    Terebelo HR
    Oncol Nurs Forum; 1991; 18(1 Suppl):5-9. PubMed ID: 1997975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment with interferon alfa-2a in the chronic phase of Philadelphia-positive chronic myeloid leukemia].
    Steegmann JL; Lavilla E; Somolinos N; Pérez-Sánchez M; Lamana M; Olmeda F; Cámara R; Arranz R; Ferro MT; Fernández-Rañada JM
    Sangre (Barc); 1992 Oct; 37(5):375-81. PubMed ID: 1293778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.
    Guilhot F; Chastang C; Michallet M; Guerci A; Harousseau JL; Maloisel F; Bouabdallah R; Guyotat D; Cheron N; Nicolini F; Abgrall JF; Tanzer J
    N Engl J Med; 1997 Jul; 337(4):223-9. PubMed ID: 9227927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.